Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.

Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mäder U, Gasser M, Waaga-Gasser AM, Eilers M, Germer CT.

PLoS One. 2013 Oct 1;8(10):e75292. doi: 10.1371/journal.pone.0075292. eCollection 2013.

2.

Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.

Liu N, He QM, Chen JW, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Ma J.

Mol Cancer. 2014 May 19;13:111. doi: 10.1186/1476-4598-13-111.

3.

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A.

J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26.

PMID:
19470954
4.

Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.

Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC, Teng HW.

J Cancer Res Clin Oncol. 2014 Apr;140(4):561-71. doi: 10.1007/s00432-014-1596-4. Epub 2014 Feb 4.

PMID:
24493623
5.

CIP2A inhibits PP2A in human malignancies.

Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J.

Cell. 2007 Jul 13;130(1):51-62.

6.

CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.

Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J.

Oncogene. 2012 Sep 27;31(39):4266-78. doi: 10.1038/onc.2011.599. Epub 2012 Jan 16.

PMID:
22249265
7.

Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.

Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ, Chan EK.

Mol Biol Cell. 2013 Jun;24(11):1638-48, S1-7. doi: 10.1091/mbc.E12-12-0891. Epub 2013 Apr 3.

8.

CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.

Guo Z, Liu D, Su Z.

Tumour Biol. 2015 Jun;36(6):4777-83. doi: 10.1007/s13277-015-3129-4. Epub 2015 Jan 31. Erratum in: Tumour Biol. 2015 Aug;36(8):6587.

PMID:
25636449
9.

CIP2A is a predictor of poor prognosis in colon cancer.

Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW, Chen KF.

J Gastrointest Surg. 2012 May;16(5):1037-47. doi: 10.1007/s11605-012-1828-3. Epub 2012 Feb 11.

PMID:
22328001
10.

CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.

Guo Z, Liu D, Su Z.

Tumour Biol. 2015 May;36(5):3583-9. doi: 10.1007/s13277-014-2995-5. Epub 2015 Jan 6. Erratum in: Tumour Biol. 2015 Aug;36(8):6587.

PMID:
25560487
11.

CIP2A regulates proliferation and apoptosis of multiple myeloma cells.

Zheng Z, Qiao Z, Chen W, Gong R, Wang Y, Xu L, Ma Y, Zhang L, Lu Y, Jiang B, Li G, Dong C.

Mol Med Rep. 2016 Sep;14(3):2705-9. doi: 10.3892/mmr.2016.5553. Epub 2016 Jul 27.

PMID:
27484817
12.

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.

Zhai M, Cong L, Han Y, Tu G.

Tumour Biol. 2014 Feb;35(2):1123-8. doi: 10.1007/s13277-013-1150-z. Epub 2013 Sep 8.

PMID:
24014087
13.

CIP2A increases self-renewal and is linked to Myc in neural progenitor cells.

Kerosuo L, Fox H, Perälä N, Ahlqvist K, Suomalainen A, Westermarck J, Sariola H, Wartiovaara K.

Differentiation. 2010 Jul;80(1):68-77. doi: 10.1016/j.diff.2010.04.003. Epub 2010 May 5.

PMID:
20447748
14.

CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.

Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, Xu D.

Clin Cancer Res. 2008 Jun 15;14(12):3722-8. doi: 10.1158/1078-0432.CCR-07-4137.

15.

Role of CIP2A in the antitumor effect of bortezomib in colon cancer.

Ding Y, Wang Y, Ju S, Wu X, Zhu W, Shi F, Mao L.

Mol Med Rep. 2014 Jul;10(1):387-92. doi: 10.3892/mmr.2014.2173. Epub 2014 Apr 24.

PMID:
24789441
16.

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM, Chen KF.

Breast Cancer Res. 2014 Sep 17;16(5):431. doi: 10.1186/s13058-014-0431-9.

17.

Estradiol enhances CIP2A expression by the activation of p70 S6 kinase.

Choi YA, Koo JS, Park JS, Park MY, Jeong AL, Oh KS, Yang Y.

Endocr Relat Cancer. 2014 Jan 30;21(2):189-202. doi: 10.1530/ERC-13-0453. Print 2014 Apr.

18.

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Lucas CM, Harris RJ, Holcroft AK, Scott LJ, Carmell N, McDonald E, Polydoros F, Clark RE.

Leukemia. 2015 Jul;29(7):1514-23. doi: 10.1038/leu.2015.71. Epub 2015 Mar 13.

PMID:
25765543
19.

CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.

Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM, Jäättelä M.

J Cell Biol. 2014 Mar 3;204(5):713-27. doi: 10.1083/jcb.201304012.

20.

CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.

Lei N, Peng B, Zhang JY.

Oncol Rep. 2014 Oct;32(4):1689-94. doi: 10.3892/or.2014.3375. Epub 2014 Aug 1.

Supplemental Content

Support Center